Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 717598, 5 pages
Clinical Study

Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience

1Department of Ophthalmology, University Hospital of León, 24071 León, Spain
2Uveitis Unit, University Hospital of León, 24071 León, Spain
3Institute of Biomedicine (INBIOMED), University of León, León, Spain
4Department of Rheumatology, University Hospital “Marques de Valdecilla”, IFIMAV, 39008 Santander, Spain
5Department of Ophthalmology, University Hospital “Clínic”, 08036 Barcelona, Spain
6Department of Rheumatology, University Hospital of León, 24071 León, Spain
7Department of Immunology, University Hospital of León, 24071 León, Spain

Received 9 March 2014; Revised 25 April 2014; Accepted 12 May 2014; Published 28 May 2014

Academic Editor: Dennis Daniel Taub

Copyright © 2014 Miguel Cordero-Coma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy. Methods. Nonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients. Results. Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20–38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68, ) and mean 1 mm central retinal thickness (317 versus 261.2 μ, ) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed. Conclusions. GLM is a new and promising therapeutic option for patients with severe and refractory uveitis.